Rhumbline Advisers Brooklyn Immuno Therapeutics, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.48 - $2.03 $12,275 - $51,913	-25,573 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.76 - $4.84 $13,884 - $38,182	7,889 Added 44.61%	25,573 $52,000
Q4 2021 Feb 10, 2022	SELL	$4.17 - $9.79 $112 - $264	-27 Reduced 0.15%	17,684 $74,000
Q3 2021 Nov 12, 2021	BUY	$8.86 - $17.05 $27,386 - $52,701	3,091 Added 21.14%	17,711 $165,000
Q2 2021 Aug 05, 2021	BUY	$3.75 - $78.5 $54,825 - $1.15 Million	14,620 New	14,620 $263,000

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.